Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834535 · ClinicalTrials.gov registry record · Phase 1
Cefdinir Capsules 300 mg, Non-fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00834535: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834535 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834535, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting conditions.
Interventions
- DRUG Cefdinir Capsules 300 mg
- DRUG OMNICEF® Capsule 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834535
The ClinicalTrials.gov registry entry for NCT00834535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefdinir Capsules 300 mg is the first listed.
NCT00834535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834535 about?
NCT00834535 is a clinical study titled "Cefdinir Capsules 300 mg, Non-fasting". This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg c...
What is the current status of trial NCT00834535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-07. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00834535?
The interventions under investigation include: Cefdinir Capsules 300 mg (DRUG), OMNICEF® Capsule 300 mg (DRUG).
Who is sponsoring clinical trial NCT00834535?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.